Ieq Capital LLC Buys Shares of 66,567 Vir Biotechnology, Inc. $VIR

Ieq Capital LLC purchased a new position in Vir Biotechnology, Inc. (NASDAQ:VIR) in the second quarter, HoldingsChannel reports. The institutional investor purchased 66,567 shares of the company’s stock, valued at approximately $678,000.

A number of other institutional investors have also recently made changes to their positions in VIR. AQR Capital Management LLC lifted its holdings in shares of Vir Biotechnology by 2,088.4% during the 1st quarter. AQR Capital Management LLC now owns 268,297 shares of the company’s stock worth $1,739,000 after acquiring an additional 256,037 shares during the last quarter. Jacobs Levy Equity Management Inc. bought a new position in Vir Biotechnology in the first quarter valued at $359,000. Goldman Sachs Group Inc. raised its position in Vir Biotechnology by 43.6% during the first quarter. Goldman Sachs Group Inc. now owns 742,674 shares of the company’s stock valued at $4,813,000 after purchasing an additional 225,544 shares in the last quarter. Woodline Partners LP raised its position in Vir Biotechnology by 245.6% during the first quarter. Woodline Partners LP now owns 466,737 shares of the company’s stock valued at $3,024,000 after purchasing an additional 331,701 shares in the last quarter. Finally, Focus Partners Wealth lifted its stake in Vir Biotechnology by 15.3% during the first quarter. Focus Partners Wealth now owns 19,317 shares of the company’s stock worth $125,000 after purchasing an additional 2,566 shares during the last quarter. Institutional investors own 65.32% of the company’s stock.

Insider Activity at Vir Biotechnology

In other news, Director Janet Napolitano sold 3,200 shares of the company’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $9.45, for a total transaction of $30,240.00. Following the completion of the transaction, the director directly owned 21,216 shares of the company’s stock, valued at approximately $200,491.20. This represents a 13.11% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 2.90% of the company’s stock.

Analysts Set New Price Targets

VIR has been the subject of a number of research reports. Leerink Partners upped their price objective on Vir Biotechnology from $20.00 to $21.00 and gave the stock an “outperform” rating in a report on Wednesday, June 3rd. Weiss Ratings restated a “sell (d-)” rating on shares of Vir Biotechnology in a research report on Wednesday, July 8th. Morgan Stanley set a $25.00 target price on Vir Biotechnology in a research note on Thursday, August 6th. Wall Street Zen upgraded shares of Vir Biotechnology from a “sell” rating to a “hold” rating in a research report on Saturday, August 8th. Finally, HC Wainwright reissued a “buy” rating on shares of Vir Biotechnology in a research note on Monday, August 10th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $21.57.

Vir Biotechnology Stock Up 2.1%

Shares of NASDAQ VIR opened at $11.31 on Friday. The firm’s fifty day moving average is $9.56 and its 200 day moving average is $9.29. Vir Biotechnology, Inc. has a 52 week low of $4.75 and a 52 week high of $11.66. The company has a market cap of $1.91 billion, a price-to-earnings ratio of -6.08 and a beta of 1.66.

Vir Biotechnology (NASDAQ:VIR) last announced its quarterly earnings results on Wednesday, August 5th. The company reported $0.47 earnings per share for the quarter, beating the consensus estimate of $0.33 by $0.14. The business had revenue of $238.95 million during the quarter, compared to analysts’ expectations of $135.88 million. Vir Biotechnology had a negative net margin of 638.88% and a negative return on equity of 29.99%. The firm’s revenue for the quarter was up 19582.5% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.80) EPS. Equities research analysts anticipate that Vir Biotechnology, Inc. will post -1.84 earnings per share for the current year.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc is a clinical‐stage immunology company dedicated to developing therapies that prevent and treat serious infectious diseases. The company leverages a suite of proprietary technology platforms—ranging from antibody isolation and screening tools to cell‐based assays and bioinformatics—to identify and advance antiviral and antibacterial candidates. Its scientific approach centers on harnessing the human immune system through monoclonal antibodies and immunomodulatory agents.

The company’s pipeline includes product candidates targeting influenza A, COVID‐19, HIV, hepatitis B, and tuberculosis.